December 15th, 2015

Bull of the Day: Biogen Idec (BIIB)

Biogen Idec (BIIB) reported third-quarter earnings of $1.33 per share, well above the year-ago figure of $1.20 and the Zacks Consensus Estimate of $1.09. Revenue increased 5% to $1.2 billion, with MS treatments Tysabri and Avonex being the primary growth drivers. Based on third quarter results, Biogen’s new guidance for 2010 and the impact of [...]
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.